FLT3 and acute myeloid leukemia: In a Sormain trial, a 2-year relapse-free survival of 85% was shown in the sorafenib group vs. a 2-year RFS of 53.3% in the placebo (HR 0.39, 95% CI; 0.18–0.85; p = 0.0135) as maintenance therapy post-allogeneic stem cell transplantation for FLT3-ITD-positive AML [23].